Evidence
Alzheimers Dement (Amst). 2024 Feb 23;16(1):e12556. doi: 10.1002/dad2.12556. eCollection 2024 Jan-Mar.
ABSTRACT
The relation between cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) and magnetic resonance imaging (MRI) measures is poorly understood in cognitively healthy individuals from the general population. Participants’ (n = 226) mean age was 70.9 years (SD = 0.4). CSF concentrations of amyloid beta (Aβ)1-42, total tau (t-tau), phosphorylated tau (p-tau), neurogranin, and neurofilament light, and volumes of hippocampus, amygdala, total basal forebrain (TBF), and cortical thickness were measured. Linear associations between CSF biomarkers and MRI measures were investigated. In Aβ1-42 positives, higher t-tau and p-tau were associated with smaller hippocampus (P = 0.001 and P = 0.003) and amygdala (P = 0.005 and P = 0.01). In Aβ1-42 negatives, higher t-tau, p-tau, and neurogranin were associated with larger TBF volume (P = 0.001, P = 0.001, and P = 0.01). No associations were observed between the CSF biomarkers and an AD signature score of cortical thickness. AD-specific biomarkers in cognitively healthy 70-year-olds may be related to TBF, hippocampus, and amygdala. Lack of association with cortical thickness might be due to early stage of disease.
PMID:38406609 | PMC:PMC10884990 | DOI:10.1002/dad2.12556
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Association of CSF biomarkers with MRI brain changes in Alzheimer’s disease
🌐 90 Days
VR Related Evidence Matrix
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia
- Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study
- Biomarkers - Part 1
- CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease
- Cerebrospinal fluid a-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Total Tau Protein Mediates the Association of Ischemic Cerebrovascular Disease with Cognitive Decline
- Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- Physical activity may a probably protective factor for postoperative delirium: the PNDABLE study
- Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)
- The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy
- Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment
- Day-to-day sleep variability with Alzheimer's biomarkers in at-risk elderly
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Neurofilament light chain is elevated in patients with newly diagnosed idiopathic intracranial hypertension: A prospective study
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort
- APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease
- a-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
- Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
- The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome
- CO2 cerebrovascular reactivity measured with CBF-MRI in older individuals: Association with cognition, physical function, amyloid, and tau proteins
- Tau accumulation and its spatial progression across the Alzheimer's disease spectrum
- Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
- G-protein coupled estrogen receptor 1, amyloid-β, and tau tangles in older adults
- Impact of amyloid and tau positivity on longitudinal brain atrophy in cognitively normal individuals
- Three-dimensional histology reveals dissociable human hippocampal long-axis gradients of Alzheimer's pathology
- D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease
- Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants
- Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies
- Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients
- The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes
- Inferior Frontal Sulcal Hyperintensities on Brain MRI Are Associated with Amyloid Positivity beyond Age-Results from the Multicentre Observational DELCODE Study
- Abnormal EEG microstates in Alzheimer's disease: predictors of b-amyloid deposition degree and disease classification
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals
- Present and future of Blood-Based biomarkers of Alzheimer's Disease: Beyond the classics
- In vivo PET classification of tau pathologies in patients with frontotemporal dementia
- Genome-wide epistasis analysis reveals gene-gene interaction network on an intermediate endophenotype P-tau/Aβ42 ratio in ADNI cohort
- Lateral geniculate body is spared of tau pathology in Pick disease
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model
- Fixel-based analysis reveals tau-related white matter changes in early stages of Alzheimer's disease
- Longitudinal analysis of CSF HIV RNA in untreated people with HIV: Identification of CSF controllers
- Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial
- Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging
- Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging
- Association of beta-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia
- Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
- Predicting functional decline in aging and Alzheimer's disease with PET-based Braak staging
- Plasma Leptin and Alzheimer Protein Pathologies Among Older Adults
- Data-driven decomposition and staging of flortaucipir uptake in Alzheimer's disease
Evidence Blueprint
Association of CSF biomarkers with MRI brain changes in Alzheimer’s disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Association of CSF biomarkers with MRI brain changes in Alzheimer’s disease
🌐 365 Days
VR Related Evidence Matrix
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression
- The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia
- Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study
- Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg
- Biomarkers - Part 1
- CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly
- Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study
- Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy
- Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains
- Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms
- Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals
- Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology
- CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease
- Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Blood-brain barrier breakdown is linked to tau pathology and neuronal injury in a differential manner according to amyloid deposition
- Cerebrospinal fluid a-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Total Tau Protein Mediates the Association of Ischemic Cerebrovascular Disease with Cognitive Decline
- Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics
- Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients
- Differential Associations of APOEɛ2 and APOEɛ4 Genotypes with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in Individuals Without Dementia
- Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- CSF metabolites associated with biomarkers of Alzheimer's disease pathology
- High burdens of phosphorylated tau protein and distinct precuneus atrophy in sporadic early-onset Alzheimer's disease
- Prevalence and Clinical Implications of a β-Amyloid-Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
- Association of Cortical and Subcortical Microstructure with Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease
- Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
- Matrix metalloproteinases are associated with brain atrophy in cognitively unimpaired individuals
- NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to Mild Cognitive Impairment
- Evaluation of SP3 for antibody-free quantification of tau in CSF mimic and brain by mass spectrometry
- CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- Mechanisms behind changes of neurodegeneration biomarkers in plasma induced by sleep deprivation
- Physical activity may a probably protective factor for postoperative delirium: the PNDABLE study
- Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in non-demented adults: The CABLE study
- Associations of cerebrospinal fluid complement proteins with Alzheimer's pathology, cognition, and brain structure in non-dementia elderly
- Potential Utility of Plasma Biomarker Panels in Differential Diagnosis of Alzheimer's Disease
- CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration
- Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals
- Global brain activity and its coupling with cerebrospinal fluid flow is related to tau pathology
- APOEε4 potentiates amyloid β effects on longitudinal tau pathology
- Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity
- Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)
- Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study
- Neurodegeneration or dysfunction in Phelan-McDermid syndrome? A multimodal approach with CSF and computational MRI
- Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images
- The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy
- A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
- Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)
- Perioperative changes in neurocognitive and Alzheimer's disease-related cerebrospinal fluid biomarker in older patients randomised to isoflurane or propofol for anaesthetic maintenance
- Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings
- Temporal Profiles of P-tau, T-tau and P-tau:T-tau Ratios in CSF and Blood from Moderate-Severe TBI Patients and Relationship to 6-12 Months Global Outcomes
- Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment
- Day-to-day sleep variability with Alzheimer's biomarkers in at-risk elderly
- The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa